| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Shafeie, Samrand, 1984-, et al.
(författare)
-
Tracking of high-temperature thermal expansion and transport properties vs. oxidation state of cobalt between +2 and +3 in the La2Co1+z(Ti1-xMgx)(1-z)O-6-system
- 2012
-
Ingår i: Journal of Materials Chemistry. - : Royal Society of Chemistry (RSC). - 0959-9428 .- 1364-5501. ; 22:32, s. 16269-16276
-
Tidskriftsartikel (refereegranskat)abstract
- The high-temperature thermal expansion and electronic transport properties of the B-site substituted LaCoO3 with both variable oxidation state of cobalt between +2 and +3 (La2Co(Ti1-xMgx)O-6, 0 <= x <= 0.5) and variable Co3+-content relative to the other B-cations (La2Co1+z(Ti0.5Mg0.5)(1-z)O-6, 0.2 <= z <= 0.6) have been investigated. Based on the temperature dependence of the thermal expansion, electronic transport properties and Seebeck coefficient, three different groups of compositions according to their symmetries can be allocated. It was found that the thermal expansion coefficients (TECs) of the studied compounds are mainly dependent on the proportion of Co2+/Co3+. For La2Co(Ti1-xMgx)O-6, the TEC increases from similar to 9 (x = 0) to similar to 19 ppm K-1 (x = 0.5) with an increase of the oxidation state of cobalt from +2 to +3, respectively. The TECs of La2Co1+z(Ti0.5Mg0.5)(1-z)O-6, z = 0.2-0.6 with Co3+-only, remain constant at similar to 21 ppm K-1 independent of the cobalt content. Thermoelectric measurements of the system indicate that all samples in the system, except La2Co1.6(Ti0.5Mg0.5)(0.4)O-6, are p-type conductors over the whole temperature range, 300 < T < 1175 K. The conductivities were found to increase with an increase of both Co3+ and total cobalt content and are described with a small polaron hopping model. Due to an insignificant number of oxygen vacancies of La2Co1+z(Ti1-xMgx)(1-z)O-6 samples prepared in air at elevated temperatures, the investigated system is proposed as an excellent model system for the investigation of the influence of the Co oxidation state and stoichiometry on different properties in perovskite cobalt oxides.
|
|
| 10. |
- Vesikari, Timo, et al.
(författare)
-
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
- 2006
-
Ingår i: N Engl J Med. - 1533-4406. ; 354:1, s. 23-33
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Rotavirus is a leading cause of childhood gastroenteritis and death worldwide. METHODS: We studied healthy infants approximately 6 to 12 weeks old who were randomly assigned to receive three oral doses of live pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine containing human serotypes G1, G2, G3, G4, and P[8] or placebo at 4-to-10-week intervals in a blinded fashion. Active surveillance was used to identify subjects with serious adverse and other events. RESULTS: The 34,035 infants in the vaccine group and 34,003 in the placebo group were monitored for serious adverse events. Intussusception occurred in 12 vaccine recipients and 15 placebo recipients within one year after the first dose including six vaccine recipients and five placebo recipients within 42 days after any dose (relative risk, 1.6; 95 percent confidence interval, 0.4 to 6.4). The vaccine reduced hospitalizations and emergency department visits related to G1-G4 rotavirus gastroenteritis occurring 14 or more days after the third dose by 94.5 percent (95 percent confidence interval, 91.2 to 96.6 percent). In a nested substudy, efficacy against any G1-G4 rotavirus gastroenteritis through the first full rotavirus season after vaccination was 74.0 percent (95 percent confidence interval, 66.8 to 79.9 percent); efficacy against severe gastroenteritis was 98.0 percent (95 percent confidence interval, 88.3 to 100 percent). The vaccine reduced clinic visits for G1-G4 rotavirus gastroenteritis by 86.0 percent (95 percent confidence interval, 73.9 to 92.5 percent). CONCLUSIONS: This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts. The risk of intussusception was similar in vaccine and placebo recipients. (ClinicalTrials.gov number, NCT00090233.) Copyright 2006 Massachusetts Medical Society.
|
|
